[
  {
    "ts": null,
    "headline": "Viatris: A Unique S&P 500 'Fallen Angel' With Intriguing Potential",
    "summary": "Viatris emerged from Pfizer's merger with Mylan and Upjohn, trading since 2020, with a market cap of $11 billion. See why I rate VTRS stock a buy.",
    "url": "https://finnhub.io/api/news?id=24ca6bb75631099d32028415c9f8b7a65534038cdd8eba928a77cfbbaddfff75",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741072327,
      "headline": "Viatris: A Unique S&P 500 'Fallen Angel' With Intriguing Potential",
      "id": 132974289,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186846700/image_186846700.jpg?io=getty-c-w1536",
      "related": "VTRS",
      "source": "SeekingAlpha",
      "summary": "Viatris emerged from Pfizer's merger with Mylan and Upjohn, trading since 2020, with a market cap of $11 billion. See why I rate VTRS stock a buy.",
      "url": "https://finnhub.io/api/news?id=24ca6bb75631099d32028415c9f8b7a65534038cdd8eba928a77cfbbaddfff75"
    }
  }
]